Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 8/20 | 0.64 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.63 |
| ▸ | DNMT3B | Q9UBC3 | 3/20 | 0.61 |
| ▸ | FPR2 | P25090 | 2/20 | 0.54 |
| ▸ | TK1 | P04183 | 2/20 | 0.50 |
| ▸ | TK2 | O00142 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | PNP | P00491 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25837386 | 1.00 | DNMT1 (0.64) | DNMT1ADRB1DNMT3BFPR2TK1 | |
| SCHEMBL29431942 | 1.00 | DNMT1 (0.64) | DNMT1ADRB1DNMT3BFPR2TK1 | |
| SCHEMBL22299584 | 1.00 | DNMT1 (0.64) | DNMT1ADRB1DNMT3BFPR2TK1 | |
| SCHEMBL231959 | 1.00 | DNMT1 (0.64) | DNMT1ADRB1DNMT3BFPR2TK1 | |
| SCHEMBL17204628 | 0.95 | DNMT1 (0.60) | DNMT1ADRB1DNMT3BFPR2TK1 | |
| Phosphoric Acid SCHEMBL7744455 | 0.95 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BFPR2TK1 | |
| Phosphoric Acid SCHEMBL15201232 | 0.95 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BFPR2TK1 | |
| Pyrophosphoric Acid SCHEMBL14660971 | 0.92 | DNMT1 (0.60) | DNMT1ADRB1DNMT3BFPR2TK1 | |
| SCHEMBL9780849 | 0.92 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BFPR2TK1 | |
| SCHEMBL5982018 | 0.92 | DNMT1 (0.63) | DNMT1ADRB1DNMT3BFPR2TK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 241 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605397-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | TETRAGON BIOSCIENCE LTD. (IL) | 2026-04-21 | — | — | US | claimed |
| EP-4640827-A1 | RECOMBINANT TET3 ENZYMES | Ludwig-Maximilians-Universität München (DE) | 2025-10-29 | — | — | EP | claimed |
| US-20250313888-A1 | ADAPTERS, METHODS, AND COMPOSITIONS FOR DUPLEX SEQUENCING | TWINSTRAND BIOSCIENCES, INC. (US) | 2025-10-09 | — | — | US | claimed |
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | REJUVENATION TECHNOLOGIES, INC. (US) | 2025-08-21 | — | — | US | claimed |
| EP-4591940-A2 | DEOXY- CYTIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | Hemispherian AS (NO) | 2025-07-30 | — | — | EP | claimed |
| EP-4410993-A2 | REAGENTS AND ADAPTERS FOR NUCLEIC ACID SEQUENCING AND METHODS FOR MAKING SUCH REAGENTS AND ADAPTERS | Twinstrand Biosciences, Inc. (US) | 2024-08-07 | — | — | EP | claimed |
| US-20240216415-A1 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | TETRAGON BIOSCIENCES LTD. (IL) | 2024-07-04 | — | — | US | claimed |
| CN-118078850-A | Deoxycytidine or uridine derivatives for use in cancer treatment | 赫米斯弗连有限公司 | 2024-05-28 | — | — | CN | claimed |
| US-11963973-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | HEMISPHERIAN AS (NO) | 2024-04-23 | — | — | US | claimed |
| CN-113543789-B | Deoxycytidine or uridine derivatives for use in cancer treatment | 赫米斯弗连有限公司 | 2024-04-05 | — | — | CN | claimed |
| WO-2020157335-A1 | DEOXY- CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | HEMISPHERIAN AS (NO) | 2020-08-06 | — | — | WO | claimed |
| EP-3350343-B1 | METHODS AND COMPOSITIONS FOR GENOMIC TARGET ENRICHMENT AND SELECTIVE DNA SEQUENCING | PETAOMICS INC (US) | 2020-04-22 | — | — | EP | claimed |
| EP-3387152-A1 | IMPROVED ADAPTERS, METHODS, AND COMPOSITIONS FOR DUPLEX SEQUENCING | Twinstrand Biosciences, Inc. (US) | 2018-10-17 | — | — | EP | claimed |
| EP-3350343-A1 | METHODS AND COMPOSITIONS FOR GENOMIC TARGET ENRICHMENT AND SELECTIVE DNA SEQUENCING | Petaomics, Inc. (US) | 2018-07-25 | — | — | EP | claimed |
| US-20170211140-A1 | ADAPTERS, METHODS, AND COMPOSITIONS FOR DUPLEX SEQUENCING | TWINSTRAND BIOSCIENCES, INC. | 2017-07-27 | — | — | US | claimed |
| WO-2017100441-A1 | IMPROVED ADAPTERS, METHODS, AND COMPOSITIONS FOR DUPLEX SEQUENCING | TWINSTRAND BIOSCIENCES, INC. (US) | 2017-06-15 | — | — | WO | claimed |
| WO-2017049213-A1 | METHODS AND COMPOSITIONS FOR GENOMIC TARGET ENRICHMENT AND SELECTIVE DNA SEQUENCING | PetaOmics, Inc. (US) | 2017-03-23 | — | — | WO | claimed |
| US-8206935-B2 | Method of rapidly quantifying hydroxymethylated DNA | LI WEIWEI (US) | 2012-06-26 | — | — | US | claimed |
| WO-2012016145-A2 | MITOCHONDRIAL APOPTOSIS-INDUCED INFLAMMATION | CEDARS-SINAI MEDICAL CENTER (US) | 2012-02-02 | — | — | WO | claimed |
| US-20120003663-A1 | Method of rapidly quantifying hydroxymethylated DNA | LI WEIWEI (US) | 2012-01-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263678-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF RNA | RNASE1, POLRMT, TERT | DNMT1 384/4885ADRB1 4067/4885DNMT3B 303/4885 |
| US-11963973-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | UMPS, UPP1, TYMP | DNMT1 697/4885ADRB1 1973/4885DNMT3B 1054/4885 |
| US-20240216415-A1 | DEOXY-CYTIDINE OR URIDINE DERIVATIVES FOR USE IN CANCER THERAPIES | UMPS, UPP1, TYMP | DNMT1 667/4885ADRB1 1969/4885DNMT3B 1007/4885 |
| US-12605397-B2 | Deoxy-cytidine or uridine derivatives for use in cancer therapies | CDA, DCTD, RNMT | DNMT1 268/4885ADRB1 1859/4885DNMT3B 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.